Nektar Therapeutics (NKTR)

16.10
NASDAQ
Prev Close 16.10
Day Low/High 0.00 / 0.00
52 Wk Low/High 9.16 / 17.55
Exchange NASDAQ
Shares Outstanding 136.26B
Market Cap 2.07B
Div & Yield N.A. (N.A)

Latest News

Nektar Therapeutics Announces Executive Management Promotions

Nektar Therapeutics Announces Executive Management Promotions

John Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President & Chief Financial Officer of Nektar

Nektar Therapeutics (NKTR) Weak On High Volume Today

Nektar Therapeutics (NKTR) Weak On High Volume Today

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

Novice Trade: Nektar Therapeutics

Plus an update on the Urban Outfitters trade from yesterday.

Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat

Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat

Nektar Therapeutics (NKTR) stock is declining on Wednesday afternoon despite posting better-than-expected 2015 fourth quarter results after yesterday’s closing bell.

Baxalta Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings

Baxalta Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings

- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], currently FDA-approved for adolescent and adult hemophilia A patients 12 years and older, offers proven prophylaxis with a simple, twice-weekly dosing schedule

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

General Motors, MetLife and Tesla: Doug Kass' Views

General Motors, MetLife and Tesla: Doug Kass' Views

Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.

Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research

Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research

New Paper Documents Durable Anti-Tumor Efficacy, Safety and Immune Mechanism of Action of NKTR-214 in Multiple Tumor Models as well as a Favorable Safety Profile in Non-Human Primates (NHPs)

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

- Topline results find no inhibitors to ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], treatment were reported and nearly 73 percent of treated patients experienced zero joint bleeds

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase...

Baxalta Presents Additional Data On Newly-Approved ADYNOVATE And Plans For New Indications During 57th American Society Of Hematology (ASH) Annual Meeting

Baxalta Presents Additional Data On Newly-Approved ADYNOVATE And Plans For New Indications During 57th American Society Of Hematology (ASH) Annual Meeting

- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] is built on ADVATE [Antihemophilic Factor (Recombinant)], offering proven bleed protection with a simple, twice-weekly dosing schedule

Baxalta Announces U.S. Availability Of ADYNOVATE, A New Treatment For Adult Patients With Hemophilia A With A Simple, Twice-Weekly Dosing Schedule

Baxalta Announces U.S. Availability Of ADYNOVATE, A New Treatment For Adult Patients With Hemophilia A With A Simple, Twice-Weekly Dosing Schedule

- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], approved by the FDA in November, is built on ADVATE [Antihemophilic Factor (Recombinant)], which been used by Hemophilia A patients worldwide for more than 12 years

Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out

Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out

A rally to $19 could ensue for Nektar (NKTR) shares.

Baxalta To Advance Care For Hemophilia A Patients With FDA Approval Of ADYNOVATE, A Simple, Twice-weekly Treatment To Reduce Bleeds

Baxalta To Advance Care For Hemophilia A Patients With FDA Approval Of ADYNOVATE, A Simple, Twice-weekly Treatment To Reduce Bleeds

- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] is built on ADVATE [Antihemophilic Factor (Recombinant)], a well-established treatment for hemophilia A patients with more than 12 years of patient experience